These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15580235)

  • 1. New technologies deliver in treating neurological diseases.
    Singer E
    Nat Med; 2004 Dec; 10(12):1267. PubMed ID: 15580235
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects of treating neurological diseases by gene therapy.
    Lundstrom K
    Curr Opin Investig Drugs; 2007 Jan; 8(1):34-40. PubMed ID: 17263183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference: a tool for querying nervous system function and an emerging therapy.
    Davidson BL; Boudreau RL
    Neuron; 2007 Mar; 53(6):781-8. PubMed ID: 17359914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting neurological disease with RNAi.
    Lingor P; Bähr M
    Mol Biosyst; 2007 Nov; 3(11):773-80. PubMed ID: 17940660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribonucleic acid interference for neurological disorders: candidate diseases, potential targets, and current approaches.
    Federici T; Boulis NM
    Neurosurgery; 2007 Jan; 60(1):3-15; discussion 15-6. PubMed ID: 17228249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the human genome.
    Tachikawa K; Briggs SP
    Curr Opin Biotechnol; 2006 Dec; 17(6):659-65. PubMed ID: 17085035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of RNA interference for neurological disorders.
    Sah DW
    Life Sci; 2006 Oct; 79(19):1773-80. PubMed ID: 16815477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of MEMS technology and engineering in medicine: a new paradigm for facial muscle reanimation.
    Cockerham K; Aro S; Liu W; Pantchenko O; Olmos A; Oehlberg M; Sivaprakasam M; Crow L
    Expert Rev Med Devices; 2008 May; 5(3):371-81. PubMed ID: 18452387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic engineering cures mice of neurological deficits: prospects for treating Angelman syndrome.
    Elgersma Y
    Pharmacogenomics; 2007 Jun; 8(6):539-41. PubMed ID: 17559342
    [No Abstract]   [Full Text] [Related]  

  • 10. Allele-specific RNA interference for neurological disease.
    Rodriguez-Lebron E; Paulson HL
    Gene Ther; 2006 Mar; 13(6):576-81. PubMed ID: 16355113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building better bugs to deliver biologics in intestinal inflammation.
    Barrett KE
    Gut; 2010 Apr; 59(4):427-8. PubMed ID: 20332513
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-viral gene transfection technologies for genetic engineering of stem cells.
    Jo J; Tabata Y
    Eur J Pharm Biopharm; 2008 Jan; 68(1):90-104. PubMed ID: 17870447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered human neural stem cells for brain repair in neurological diseases.
    Kim SU
    Brain Dev; 2007 May; 29(4):193-201. PubMed ID: 17303360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference based gene therapy for neurological disease.
    Jagannath A; Wood M
    Brief Funct Genomic Proteomic; 2007 Mar; 6(1):40-9. PubMed ID: 17478451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA: an emerging therapeutic.
    Scaria V; Hariharan M; Brahmachari SK; Maiti S; Pillai B
    ChemMedChem; 2007 Jun; 2(6):789-92. PubMed ID: 17410618
    [No Abstract]   [Full Text] [Related]  

  • 17. Cell microencapsulation technology: towards clinical application.
    Murua A; Portero A; Orive G; Hernández RM; de Castro M; Pedraz JL
    J Control Release; 2008 Dec; 132(2):76-83. PubMed ID: 18789985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New techniques for screening drugs targeting at RNAs].
    Wu GF
    Yao Xue Xue Bao; 2005 Dec; 40(12):1064-8. PubMed ID: 16496666
    [No Abstract]   [Full Text] [Related]  

  • 19. Directed evolution for drug and nucleic acid delivery.
    Hida K; Hanes J; Ostermeier M
    Adv Drug Deliv Rev; 2007 Dec; 59(15):1562-78. PubMed ID: 17933418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.